Estimation of the use of fibrin and collagen membranes as carriers for platelet-derived growth factor-BB (PDGF-BB) in the presence of amoxicillin.

The effect of homogeneous fibrin (Fb), collagen (Coll) and composite fibrin-heparin (Fb-Hp), fibrin-collagen (Fb-Coll) membranes on in vitro release of platelet-derived growth factor (PDGF-BB) was evaluated in the presence or absence of amoxicillin using of the ELISA immunoassay test. Amoxicillin concentration was determined spectrophotometrically at 272 nm. The process of the PDGF-BB growth factor and amoxicillin release from the studied membranes was of a two-phase nature in the majority of the systems analysed. The PDGF-BB was released in the highest amount from the Coll membrane (M7) without the presence of amoxicillin – 546.2 ±7.47 pg, t0.5 = 0.88 h and 202.5 ± 6.83 pg, t0.5 = 26.65 h during the first phase and second phase, respectively. The lowest PDGF-BB release was observed from composite M4 (Fb-Hp) membrane – 5.88 ± 0.81 pg, t0.5 = 1.69 h; and 110.2 ± 6.48 pg, t0.5 = 855.6 h during first and second phase respectively. An optimal release of amoxicillin was observed in the case of the composite M6 (Fb-Coll) membrane – only in the second phase: 64.2 ± 7.8 mg, t0.5 = 83.5 h. The lowest and delayed amoxicillin release was achieved for M4 membrane (approx. 17.1 ± 1.12 mg, t0.5 = 46.5 h). The results of the PDGF-BB release and amoxicillin from membranes indicated a correlation between the level of release and composition of the film. Our results suggested that fibrin and collagen membranes may be beneficial to enhance periodontal bone regeneration.

Concentrações inibitórias mínimas de amoxicilina em medicamento referência, genérico e similar / Minimum inhibitory concentration of different presentations of amoxicilin

Os estreptococos do grupo viridans são organismos comumente associados à endocardite após extrações dentais. Por isso, a profilaxia adotada antes desses procedimentos envolve o uso de penicilinas, em especial a amoxicilina. Foram determinadas as Concentrações Inibitórias Mínimas (MIC) de diferentes apresentações de amoxicilina (medicamento de referência, genérico e similar) frente cepas-padrão de estreptococos orais. Não foram detectadas diferenças estatísticas significativas na eficácia das diferentes categorias de amoxicilina e o antibiótico mostrou potência superior à preconizada pela legislação vigente.